简介:Thekeratoprosthesis(KPro;artificialcornea)isaspecialrefractivedevicetoreplacehumancorneabyusingheterogeneousformingmaterialsfortheimplantationintothedamagedeyesinordertoobtainacertainvision.Themainproblemsofartificialcorneaarethebiocompatibilityandstabilityofthetissueparticularlyinpenetratingkeratoplasty.Thecurrentstudiesoftissue-engineeredscaffoldmaterialsthroughcomprisingcompositesofnaturalandsyntheticbiopolymerstogetherhavedevelopedanewwaytoartificialcornea.Althoughawideagreementthatthelong-termstabilityofthesedeviceswouldbegreatlyimprovedbythepresenceofcorneacells,modificationofkeratoprosthesistosupportcorneacellsremainselusive.Mostofthestudiesoncornealsubstratematerialsandsurfacemodificationofcompositeshavetriedtoimprovethegrowthandbiocompatibilityofcorneacellswhichcannotonlyreducethestimulusofheterogeneousmaterials,butalsomoreimportantlycontinuousandstablecorneacellscanpreventthedestructionofcollagenase.Thenecrosisofstromaandspontaneousextrusionofthedevice,allowformaintenanceofaprecornealtearlayer,andplaytheroleofensuringagoodopticalsurfaceandresistingbacterialinfection.Asaresult,improvementincornealcellshasbeenthemainaimofseveralrecentinvestigations;someefforthasfocusedonbiomaterialforitswellbiologicalpropertiessuchaspromotingthegrowthofcorneacells.Thepurposeofthisreviewistosummarythegrowthstatusofthecornealcellsaftertheimplantationofseveralartificialcorneas.
简介:以“Antinociception”、“Anodyne”、“paregoric”、“Aceodyne”“Analgesic”、“Reducepain”、“Analgetic”、“Analesic”、“Odgnolysis”、“Stoppain”、“Pain-killer”、“Paincontrol”、“Antinociceptiveeffect”、“Reliefpain”、“Relievepain”为主题词,在Pubmed数据库中查找2007年7月至2012年7月发表的相关文献,通过查阅文章题目和摘要筛选所需中英文文章,进行归纳总结。
简介:目的:探讨和分析强化剂量阿托伐他汀对应用不同剂量非离子低渗造影剂碘帕醇患者肾功能的影响。方法:将择期行冠状动脉造影(CAG)和经皮冠状动脉介入术(PCI)患者200例,随机分为强化剂量阿托伐他汀治疗组(100例)和常规剂量阿托伐他汀治疗组(100例),在全部采用水化治疗基础上,强化组给予强化剂量阿托伐他汀口服(术前1d80mg,术前2h40mg),常规组给予常规剂量阿托伐他汀口服(术前1d20mg)。其中对进行单纯造影与造影后直接PCI术的患者根据造影剂用量的不同,分为≤120mL组和〉120mL组,分别于术前、术后测定血清肌酐(Scr)、BUN及超敏C反应蛋白(hsCRP)等指标,按Cochcroft-Gault公式计算内生肌酐清除率(Ccr),并进行统计学分析。结果:与术前相比,术后常规剂量组和强化剂量组患者Scr、BUN水平均明显升高,Ccr均明显下降(P〈0.05);常规剂量组患者hsCRP水平升高(P〈0.05),而强化剂量组hsCRP水平变化相近(P〉0.05)。强化剂量组的患者造影剂使用剂量的大小对肾功能无明显影响,≤120mL组和〉120mL组比较差异无统计学意义(P〉0.05),但常规剂量组肾功能差异具有统计学意义,表现为Scr、BUN及hsCRP水平≤120mL组较〉120mL组升高(P〈0.05),Ccr≤120mL组较〉120mL组下降(P〈0.05)。常规剂量阿托伐他汀治疗组发生